Current status of the diagnosis and treatment of chronic hepatitis B virus infection with immune control
10.3969/j.issn.1001-5256.2020.05.041
- VernacularTitle:慢性HBV感染免疫控制期的抗病毒治疗
- Author:
Lulu ZHOU
1
;
Na LIU
;
Chunxi LI
Author Information
1. Department of Infectious Diseases, Affiliated Hospital of Yan’an University, Yan’an, Shaanxi 716000, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
immune control;
diagnosis;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(5):1134-1137
- CountryChina
- Language:Chinese
-
Abstract:
Patients with chronic hepatitis B virus (HBV) infection with immune control generally have no or little liver damage, with a low incidence rate of adverse events, and spontaneous HBsAg seroclearance may occur in some patients. Most scholars do not recommend antiviral therapy for such patients in China and foreign countries. However, with the gradual aging of chronic HBV infection, patients with immune control are also faced with disease progression and the development of liver cirrhosis or liver cancer. This article introduces the clinical significance of appropriate timing of antiviral therapy for the prognosis of patients with chronic HBV infection with immune control.
